Log In
Print
BCIQ
Print
Print this Print this
 

ARN-810

  Manage Alerts
Collapse Summary General Information
Company Seragon Pharmaceuticals Inc.
DescriptionOral selective estrogen receptor degrader (SERD)
Molecular Target Estrogen receptor
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat locally advanced or metastatic estrogen receptor-positive breast cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today